8-K: QT Imaging Reports $1.4M in Scanner Sales Revenue with 56% Gross Margin in Q1 2024

QT Imaging announced its first quarter 2024 financial results, highlighting $1.4 million in scanner sales revenue and a 56% gross margin, alongside strategic partnerships and research advancements.

Summary

• QT Imaging reported $1.4 million in commercial revenue for the first quarter of 2024, a significant increase from less than $0.1 million in the same period last year.
• The company achieved a gross margin of 56% in Q1 2024, a substantial improvement from a negative margin in Q1 2023, driven by the sale and delivery of three QT Breast Scanners.
• Net loss for the quarter was $4.3 million, which includes $1.9 million of non-cash income related to changes in the fair value of warrants, derivatives, and contingent consideration from the merger with GigCapital5.
• Adjusted EBITDA for Q1 2024 was $(1.2) million, compared to $(1.1) million in Q1 2023.
• The company completed its merger with GigCapital5 on March 4, 2024, and has established a strategic sales and distribution partnership in the USA.
• A study published in Academic Radiology found that QT Imaging technology is similarly effective as digital breast tomosynthesis (DBT) or 3D mammography.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and improved gross margins, but also acknowledges a net loss and ongoing challenges. The successful merger and strategic partnerships are positive indicators, but the company is still in a transitional phase.

Positives

• The company has shown significant revenue growth, increasing from less than $0.1 million to $1.4 million in the first quarter of 2024.
• The gross margin has improved dramatically from negative to 56% in the first quarter of 2024.
• The company has successfully completed a merger with GigCapital5.
• QT Imaging has established a strategic sales and distribution partnership in the USA.
• The company's technology has been validated in a study published in Academic Radiology, showing it is similarly effective as digital breast tomosynthesis (DBT).
• The company has secured a five-year research grant from the National Institutes of Health/National Cancer Institute.

Negatives

• The company reported a net loss of $4.3 million for the first quarter of 2024.
• Adjusted EBITDA was negative at $(1.2) million for the first quarter of 2024.
• The net loss includes $4.3 million of one-time business combination transaction expenses.

Risks

• The company's ability to sell and deploy the QT Imaging Breast Acoustic CT Scanner is subject to market acceptance and competition.
• The company's ability to extend product offerings into new areas or products is subject to research and development risks.
• The company's ability to commercialize technology is subject to regulatory and market risks.
• The company's financial results are subject to fluctuations in the industry and changes in demand.
• The company's ability to attract and retain qualified personnel is subject to market conditions.
• The company's ability to obtain and access financing in the future is subject to market conditions.
• The company has identified a material weakness in its internal controls over financial reporting.

Future Outlook

2024 is a transitional year for QT Imaging as the company focuses on commercialization through strategic partnerships, with guidance for the rest of the year to be provided with the release of Q2 2024 earnings.

Management Comments

• QT Imaging CEO Dr. Raluca Dinu stated that the team has been on an incredible journey since its inception in 2012, with a mission to create disruptive innovation in medical imaging.
• Dr. Dinu also mentioned the scanner shipments made in the first quarter since the merger with GigCapital5 and the ongoing feasibility study to solidify the partnership for large-scale manufacturing.

Industry Context

This announcement highlights QT Imaging's progress in the medical device industry, particularly in breast imaging, where there is a need for safer and more accessible alternatives to traditional mammography. The company's technology competes with established methods like digital breast tomosynthesis (DBT) and aims to provide a radiation-free and compression-free option.

Comparison to Industry Standards

• The company's 56% gross margin is a strong result for a medical device company in the early stages of commercialization, although it is important to note that this is based on a small number of sales.
• The study published in Academic Radiology comparing QT Imaging technology to DBT is a significant milestone, as DBT is a widely used standard in breast cancer screening.
• Companies like Hologic and GE Healthcare are major players in the mammography market, and QT Imaging is positioning itself as a disruptive innovator with its unique technology.
• The company's focus on strategic partnerships for sales and distribution is a common approach for medical device companies looking to scale their operations.

Management Changes

Related Party Transactions

• The company entered into a Services Agreement with QT Imaging Center, owned and operated by Dr. Klock, effective April 1, 2024.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and strategic decisions.
• Employees will be impacted by the company's growth and operational changes.
• Customers will benefit from the company's innovative imaging technology.
• Suppliers will be impacted by the company's production and sales activities.
• Creditors will be impacted by the company's financial health and debt obligations.

Next Steps

• The company will continue to focus on commercialization of its scanner in the U.S. via its strategic sales and distribution partner.
• The company will continue clinical studies with partners in academia and medical institutions.
• The company will target to provide guidance for the rest of the year as part of the release of Q2'24 earnings.

Key Dates

Keywords

QT Imaging, Breast Scanner, Medical Imaging, Acoustic CT, Digital Breast Tomosynthesis, Mammography, Gross Margin, EBITDA, Merger, Strategic Partnership, Commercialization, Research Grant